A new trading day began on Friday, with Inovio Pharmaceuticals Inc (NASDAQ: INO) stock price down -6.22% from the previous day of trading, before settling in for the closing price of $2.25. INO’s price has ranged from $1.42 to $12.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 22.92% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 47.65%. With a float of $36.39 million, this company’s outstanding shares have now reached $36.67 million.
In an organization with 134 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -636.81%, operating margin of -11541102.4%, and the pretax margin is -20624824.93%.
Inovio Pharmaceuticals Inc (INO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Inovio Pharmaceuticals Inc is 0.79%, while institutional ownership is 37.18%.
Inovio Pharmaceuticals Inc (INO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 47.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.23% during the next five years compared to 22.92% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
Here are Inovio Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 276.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.62 in the next quarter and is forecasted to reach -1.79 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.49 million. That was better than the volume of 0.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 81.01%.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 75.00%, which indicates a significant increase from 52.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.18% in the past 14 days, which was lower than the 66.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.98, while its 200-day Moving Average is $3.07. However, in the short run, Inovio Pharmaceuticals Inc’s stock first resistance to watch stands at $2.24. Second resistance stands at $2.38. The third major resistance level sits at $2.49. If the price goes on to break the first support level at $2.00, it is likely to go to the next support level at $1.89. Assuming the price breaks the second support level, the third support level stands at $1.75.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
With a market capitalization of 77.38 million, the company has a total of 36,674K Shares Outstanding. Currently, annual sales are 220 K while annual income is -107,250 K. The company’s previous quarter sales were 70 K while its latest quarter income was -19,690 K.
